Evommune, Inc.
EVMN
$18.87
-$0.02-0.11%
NYSE
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
1/19/2026
-
MarketBeat
1/23/2026
-
Ticker Report
1/22/2026
-
MarketBeat
1/22/2026
-
TipRanks Financial Blog
1/22/2026
-
The Fly
1/20/2026
-
MarketBeat
1/20/2026
-
MarketBeat
1/15/2026
-
MarketBeat
1/8/2026
-
MarketBeat
1/8/2026
-
The Fly
1/8/2026
-
The Fly
1/7/2026
-
The Fly
1/7/2026
-
TipRanks Financial Blog
1/7/2026
-
The Fly
1/7/2026
-
MarketBeat
1/6/2026
-
TipRanks Financial Blog
1/6/2026
-
The Fly
1/6/2026
-
GuruFocus
1/6/2026
-
The Fly
12/29/2025
-
MarketBeat
12/26/2025
-
MarketBeat
12/23/2025
-
MarketBeat
12/22/2025
-
Zolmax
12/22/2025
-
MarketBeat
12/22/2025
-
MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Thursday, December 11, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Jul 13 and 17 (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
--
90-Day Total Return
--
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
(925) 247-4487
Address
1841 Page Mill Road
Palo Alto, CA 94304
Palo Alto, CA 94304
Country
Year Founded
Business Description
Sector
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical...
more